University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Peter R. Carroll, M.D.

Co-director of Urologic Cancer

Dr. Peter Carroll, co-director of Urologic Cancer at the UCSF Helen Diller Family Comprehensive Cancer Center and chair of Urology at UCSF, is an expert in managing urologic cancers. His areas of interest include innovative methods of urinary tract reconstruction and the impact of cancer detection and treatment on quality of life.

Carroll has authored hundreds of publications, serves as associate editor of the Journal of Urology and plays a key role in other journals. He is principal or co-investigator of many peer-reviewed research grants. Carroll holds the Ken and Donna Derr-Chevron Distinguished Professorship. He graduated with honors from Georgetown University School of Medicine and came to UCSF for general surgery training and a urology residency. He completed a fellowship in Urologic Oncology at Memorial-Sloan Kettering Cancer Center before returning to UCSF.

Read a Q&A with Carroll.

Clinics

Prostate Cancer Center
1600 Divisadero St., Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Prostate Cancer Risk and Prevention Clinic
1600 Divisadero St, Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Urologic Surgery and Oncology
1600 Divisadero St., Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about Peter R. Carroll

Education

Georgetown University 1979

Residencies

UCSF, Urology 1984

Fellowships

Memorial Sloan-Kettering Cancer Center

Selected Research and Publications

  1. Wang SY, Shiboski S, Belair CD, Cooperberg MR, Simko JP, Stoppler H, Cowan J, Carroll PR, Blelloch R. miR-19, miR-345, miR-519c-5p Serum Levels Predict Adverse Pathology in Prostate Cancer Patients Eligible for Active Surveillance. PLoS One. 2014; 9(6):e98597.
  2. Welty CJ, Cooperberg MR, Carroll PR. Meaningful end points and outcomes in men on active surveillance for early-stage prostate cancer. Curr Opin Urol. 2014 May; 24(3):288-92.
  3. Carroll PR, Vickers AJ. Point/Counterpoint: early detection of prostate cancer: do the benefits outweigh the consequences? J Natl Compr Canc Netw. 2014 May; 12(5 Suppl):768-71.
  4. Greene KL, Punnen S, Carroll PR. Evolution and immediate future of US screening guidelines. Urol Clin North Am. 2014 May; 41(2):229-35.
  5. Jarow JP, Thompson IM, Kluetz PG, Baxley J, Sridhara R, Scardino P, Carroll P, Albertsen P, Carter HB, Brawley O, Sartor O, Sandler H, Kiefert JJ, Morton RA. Drug and device development for localized prostate cancer: report of a food and drug administration/american urological association public workshop. Urology. 2014 May; 83(5):975-9.
  6. Morgan TM, Meng MV, Cooperberg MR, Cowan JE, Weinberg V, Carroll PR, Lin DW. A risk-adjusted definition of biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis. 2014 Jun; 17(2):174-9.
  7. Garcia MM, Gottschalk AR, Brajtbord J, Konety BR, Meng MV, Roach M, Carroll PR. Endoscopic gold fiducial marker placement into the bladder wall to optimize radiotherapy targeting for bladder-preserving management of muscle-invasive bladder cancer: feasibility and initial outcomes. PLoS One. 2014; 9(3):e89754.
  8. Bennett A, Gnjidic D, Gillett M, Carroll P, Matthews S, Johnell K, Fastbom J, Hilmer S. Prevalence and impact of fall-risk-increasing drugs, polypharmacy, and drug-drug interactions in robust versus frail hospitalised falls patients: a prospective cohort study. Drugs Aging. 2014 Mar; 31(3):225-32.
  9. Vickers AJ, Thompson IM, Klein E, Carroll PR, Scardino PT. A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer. Urology. 2014 Mar; 83(3):592-6.
  10. Welty CJ, Carroll PR. The ongoing need for improved risk stratification and monitoring for those on active surveillance for early stage prostate cancer. Eur Urol. 2014 Jun; 65(6):1032-3.
  11. Brajtbord JS, Punnen S, Cowan JE, Welty CJ, Carroll PR. Age and baseline quality of life at radical prostatectomy-who has the most to lose? J Urol. 2014 Aug; 192(2):396-401.
  12. Johnston C, Hilmer SN, McLachlan AJ, Matthews ST, Carroll PR, Kirkpatrick CM. The impact of frailty on pharmacokinetics in older people: using gentamicin population pharmacokinetic modeling to investigate changes in renal drug clearance by glomerular filtration. Eur J Clin Pharmacol. 2014 May; 70(5):549-55.
  13. Magbanua MJ, Richman EL, Sosa EV, Jones LW, Simko J, Shinohara K, Haqq CM, Carroll PR, Chan JM. Physical activity and prostate gene expression in men with low-risk prostate cancer. Cancer Causes Control. 2014 Apr; 25(4):515-23.
  14. Anwar M, Westphalen AC, Jung AJ, Noworolski SM, Simko JP, Kurhanewicz J, Roach M, Carroll PR, Coakley FV. Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer: Quantitative analysis of imaging contour compared to whole-mount histopathology. Radiother Oncol. 2014 Feb; 110(2):303-8.
  15. Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014 Jun; 65(6):1046-55.
  16. Glass AS, Hilton JF, Cowan JE, Washington SL, Carroll PR. Serial Prostate Biopsy and Risk of Lower Urinary Tract Symptoms: Results From a Large, Single-institution Active Surveillance Cohort. Urology. 2014 Jan; 83(1):33-9.
  17. Cary KC, Singla N, Cowan JE, Carroll PR, Cooperberg MR. Impact of Androgen Deprivation Therapy on Mental and Emotional Well-Being in Men with Prostate Cancer: Analysis from the CaPSURE™ Registry. J Urol. 2014 Apr; 191(4):964-70.
  18. Cary KC, Paciorek A, Fuldeore MJ, Carroll PR, Cooperberg MR. Temporal trends and predictors of salvage cancer treatment after failure following radical prostatectomy or radiation therapy: An analysis from the CaPSURE registry. Cancer. 2014 Feb 15; 120(4):507-12.
  19. Starobinets O, Guo R, Simko JP, Kuchinsky K, Kurhanewicz J, Carroll PR, Greene KL, Noworolski SM. Semiautomatic registration of digital histopathology images to in vivo MR images in molded and unmolded prostates. J Magn Reson Imaging. 2014 May; 39(5):1223-9.
  20. Tomaszewski JJ, Richman EL, Sadetsky N, O'Keefe DS, Carroll PR, Davies BJ, Chan JM. Impact of Folate Intake on Prostate Cancer Recurrence Following Definitive Therapy: Data from CaPSURE™. J Urol. 2014 Apr; 191(4):971-6.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.